# URGN — UroGen Pharma Ltd · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** URGN  
**Sources:** 17  
**Published:** 2026-10-03  
**Canonical:** https://app.k3vl4r.com/research/deep-research-urgn-urogen-pharma-ltd-catalysts-narrative-risks-5935

---

# UroGen Pharma Ltd. (NASDAQ: URGN) — Research Snapshot as of 2026-10-03

## Brief Profile
URGN trades on the NASDAQ and is positioned as a commercial-stage uro-oncology/biotechnology company with two marketed products — **ZUSDURI (Zusduri)** and **Jelmyto** — plus an advancing pipeline [[1]](https://www.marketbeat.com/stocks/NASDAQ/URGN/earnings/)[[8]](https://finance.yahoo.com/healthcare/articles/heres-why-add-urgn-stock-131100895.html). The stock closed at roughly **$41.40** on October 2, 2026, with a market capitalization near **$2.0B** [[11]](https://stockanalysis.com/stocks/urgn/forecast/)[[13]](https://tickernerd.com/stock/urgn-forecast/).

---

## Recent Catalysts (roughly July–October 2026)

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-urgn-urogen-pharma-ltd-catalysts-narrative-risks-5935 (free to sign up)._
